2. Search Result
Search Result
Results for "

YM09538

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-106720
    Amosulalol

    YM 09538

    		 Adrenergic Receptor Cardiovascular Disease
    Amosulalol (YM 09538) is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR) .
    Amosulalol
  • HY-106720B
    (-)-Amosulalol

    (-)-YM 09538

    		 Others Others
    (-)-Amosulalol ((-)-YM 09538) is an α,β-blocker with pharmacokinetic and metabolic activities in mice. In mice, the plasma concentration of (-)-Amosulalol decreased in a biphasic manner after intravenous injection. The time to reach the maximum plasma concentration after oral administration was 0.25h, and then decreased. The systemic bioavailability was 38.7%, and it was mainly excreted through urine. Multiple metabolites were detected in urine, and a new metabolite amosulalol carbamoyl glucuronide was found in bile samples.
    (-)-Amosulalol
  • HY-106720A
    Amosulalol hydrochloride

    YM 09538 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    Amosulalol (YM 09538) hydrochloride is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol hydrochloride exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol hydrochloride decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR) .
    Amosulalol hydrochloride
  • HY-106720C
    (+)-Amosulalol

    (+)-YM 09538

    		 Others Others
    (+)-Amosulalol ((+)-YM 09538) is an α,β-blocker with pharmacokinetic and metabolic activities in mice. In mice, the plasma concentration of (+)-Amosulalol decreased in a biphasic manner after intravenous injection. The time to reach the maximum plasma concentration after oral administration was 0.25h, and then decreased. The systemic bioavailability was 38.7%, and it was mainly excreted through urine. Multiple metabolites were detected in urine, and a new metabolite amosulalol carbamoyl glucuronide was found in bile samples.
    (+)-Amosulalol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: